NO3006443T3 - - Google Patents

Info

Publication number
NO3006443T3
NO3006443T3 NO14807340A NO14807340A NO3006443T3 NO 3006443 T3 NO3006443 T3 NO 3006443T3 NO 14807340 A NO14807340 A NO 14807340A NO 14807340 A NO14807340 A NO 14807340A NO 3006443 T3 NO3006443 T3 NO 3006443T3
Authority
NO
Norway
Application number
NO14807340A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3006443T3 publication Critical patent/NO3006443T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO14807340A 2013-06-06 2014-06-06 NO3006443T3 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013119416 2013-06-06
PCT/JP2014/065141 WO2014196644A1 (ja) 2013-06-06 2014-06-06 ベンゾチオフェン化合物

Publications (1)

Publication Number Publication Date
NO3006443T3 true NO3006443T3 (https=) 2018-09-22

Family

ID=52005968

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14807340A NO3006443T3 (https=) 2013-06-06 2014-06-06

Country Status (32)

Country Link
US (2) US8981119B2 (https=)
EP (1) EP3006443B1 (https=)
JP (1) JP6314978B2 (https=)
KR (1) KR102253721B1 (https=)
CN (1) CN105263926B (https=)
AR (1) AR096544A1 (https=)
AU (1) AU2014275768B2 (https=)
BR (1) BR112015030533B1 (https=)
CA (1) CA2914606C (https=)
CY (1) CY1120341T1 (https=)
DK (1) DK3006443T3 (https=)
ES (1) ES2671818T3 (https=)
HR (1) HRP20180722T1 (https=)
HU (1) HUE038920T2 (https=)
IL (1) IL242800B (https=)
LT (1) LT3006443T (https=)
MX (1) MX2015016743A (https=)
MY (1) MY199155A (https=)
NO (1) NO3006443T3 (https=)
PH (1) PH12015502637B1 (https=)
PL (1) PL3006443T3 (https=)
PT (1) PT3006443T (https=)
RS (1) RS57250B1 (https=)
RU (1) RU2667507C2 (https=)
SG (1) SG11201509989VA (https=)
SI (1) SI3006443T1 (https=)
SM (1) SMT201800306T1 (https=)
TR (1) TR201808724T4 (https=)
TW (1) TWI624466B (https=)
UA (1) UA117484C2 (https=)
WO (1) WO2014196644A1 (https=)
ZA (1) ZA201508866B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003357A1 (en) 2019-07-23 2022-06-01 Astellas Pharma Global Development, Inc. Methods of treating sleep disorders associated with pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614639A (en) * 1995-03-31 1997-03-25 Eli Lilly And Company Process for preparing 2-substituted benzo[b]thiophene compounds and intermediates thereof
WO2002062745A1 (en) * 2001-02-06 2002-08-15 Glaxo Group Limited Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
US7589116B2 (en) 2003-04-03 2009-09-15 Merck & Co. Inc. Biaryl substituted pyrazoles as sodium channel blockers
RU2006104621A (ru) 2003-07-15 2006-08-27 Смитклайн Бичам Корпорейшн (US) Новые соединения
WO2008054435A2 (en) * 2006-01-09 2008-05-08 The Regents Of The University Of California Use of sk channel activators to prevent relapse/reinstatement of drugs of abuse
US8022209B2 (en) * 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
CN102272152B (zh) * 2008-11-10 2014-05-28 贝林格尔.英格海姆国际有限公司 通过中电导钙激活钾通道调控细胞-细胞融合的组合物及方法
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio

Also Published As

Publication number Publication date
CN105263926B (zh) 2018-05-11
JP6314978B2 (ja) 2018-04-25
RU2667507C2 (ru) 2018-09-21
IL242800B (en) 2019-06-30
WO2014196644A1 (ja) 2014-12-11
UA117484C2 (uk) 2018-08-10
PH12015502637B1 (en) 2019-02-08
MY199155A (en) 2023-10-18
ES2671818T3 (es) 2018-06-08
RU2015152150A (ru) 2017-07-13
PL3006443T3 (pl) 2018-09-28
TWI624466B (zh) 2018-05-21
TR201808724T4 (tr) 2018-07-23
CA2914606A1 (en) 2014-12-11
CA2914606C (en) 2021-03-23
MX2015016743A (es) 2016-03-21
US20140364421A1 (en) 2014-12-11
ZA201508866B (en) 2017-11-29
TW201536775A (zh) 2015-10-01
SI3006443T1 (en) 2018-08-31
IL242800A0 (en) 2016-02-01
US20150133433A1 (en) 2015-05-14
JPWO2014196644A1 (ja) 2017-02-23
SG11201509989VA (en) 2016-01-28
LT3006443T (lt) 2018-07-10
EP3006443A1 (en) 2016-04-13
BR112015030533A2 (pt) 2020-10-20
HUE038920T2 (hu) 2018-12-28
DK3006443T3 (en) 2018-06-25
EP3006443B1 (en) 2018-04-25
CY1120341T1 (el) 2019-07-10
US8981119B2 (en) 2015-03-17
SMT201800306T1 (it) 2018-07-17
RS57250B1 (sr) 2018-07-31
EP3006443A4 (en) 2016-12-21
AR096544A1 (es) 2016-01-13
CN105263926A (zh) 2016-01-20
HRP20180722T1 (hr) 2018-06-15
BR112015030533B1 (pt) 2023-02-28
AU2014275768B2 (en) 2017-12-14
PT3006443T (pt) 2018-06-07
KR20160015281A (ko) 2016-02-12
HK1215570A1 (zh) 2016-09-02
KR102253721B1 (ko) 2021-05-18
AU2014275768A1 (en) 2015-12-17
US9399038B2 (en) 2016-07-26
PH12015502637A1 (en) 2016-03-07

Similar Documents

Publication Publication Date Title
AP2016009275A0 (https=)
BR112015007533A2 (https=)
BR102016010778A2 (https=)
BR112014017733A2 (https=)
BR112014017739A2 (https=)
BR112014019326A2 (https=)
BR112014018480A2 (https=)
BR112014017855A2 (https=)
BR112014020341A2 (https=)
BR112016010923A2 (https=)
BR112014017765A2 (https=)
BR112014017669A2 (https=)
BR112014021878A2 (https=)
BR112014019204A2 (https=)
BR112014017901A2 (https=)
BR112016015033A2 (https=)
BR112014018207A2 (https=)
BR112015015948A2 (https=)
BR112014017722A2 (https=)
BR112016002115A2 (https=)
BR112014017653A2 (https=)
BR112014017794A2 (https=)
BR112014017601A2 (https=)
BR112014017745A2 (https=)
BR112015015312A2 (https=)